Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2025-06-11 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
关于取消监事会并修订《公司章程》及制定、修订部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from a company regarding the cancellation of its supervisory board and the corresponding amendments to its Articles of Association (公司章程). It includes extensive revisions to governance documents, references to compliance with company law and stock exchange rules, and detailed changes to corporate governance structures and shareholder rights. The content focuses on governance structure changes and regulatory compliance rather than financial results or audit opinions. It is not a full annual or interim report, nor an earnings release, audit report, or legal proceeding update. It is also not a simple announcement of a report publication but a substantive governance-related disclosure. Therefore, the document fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-06-11 Chinese
《关联交易管理制度》（2025年6月修订）
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System' and details the company's policies, principles, and procedures regarding related party transactions. It includes governance rules, approval authorities, disclosure requirements, and compliance with relevant laws and regulations. The content is a governance framework document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a notice or announcement of a report. It is a governance-related internal rules document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (6897 characters) supports it being a full policy document rather than a brief announcement or certification.
2025-06-11 Chinese
《投资者关系管理制度》（2025年6月修订）
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System' and is a detailed policy document outlining the company's approach to managing investor relations, communication, and compliance with relevant laws and regulations. It does not contain financial statements, earnings data, or audit information. It is a governance-related document describing internal rules and procedures for investor relations management. It is not an announcement, transcript, or report of financial results. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-06-11 Chinese
《信息披露管理制度》（2025年6月修订）
Governance Information Classification · 95% confidence The document is titled as an "Information Disclosure Management System" for a company, detailing the principles, rules, and procedures for information disclosure. It extensively references regulatory frameworks such as the China Securities Regulatory Commission (CSRC), Shanghai Stock Exchange rules, and Chinese securities laws. The content includes detailed requirements for periodic reports (annual, semi-annual, quarterly), interim disclosures, major event disclosures, related party transactions, risk disclosures, and audit requirements. It also specifies the contents and timing of annual reports, audit reports, and interim reports, but the document itself is a policy or governance document outlining how the company manages and complies with information disclosure obligations. It does not contain actual financial data, financial statements, or audit opinions, nor is it an announcement or a brief notice. Therefore, it is best classified as a Governance Information document, as it details the company's internal rules and governance practices related to information disclosure.
2025-06-11 Chinese
《和元生物技术（上海）股份有限公司章程》（2025年6月修订）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 和元生物技术（上海）股份有限公司, dated June 2025. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, capital changes, shareholder meetings, and governance rules. It is a comprehensive internal governance document rather than a financial report or announcement. There is no indication that this is an annual report, earnings release, or any other financial filing. It is not a proxy statement or voting results announcement. The document is a formal governance document outlining the company's internal rules and structure, which fits the definition of Governance Information (CGR). The length (15,000 characters) and content confirm it is the full governance document, not a brief announcement or summary.
2025-06-11 Chinese
《防范控股股东及关联方占用公司资金管理制度》（2025年6月修订）
Governance Information Classification · 95% confidence The document is a detailed internal management system titled '防范控股股东及关联方占用公司资金管理制度' (Prevention of Controlling Shareholders and Related Parties Occupying Company Funds Management System) issued by 和元生物技术（上海）股份有限公司. It outlines principles, responsibilities, and procedures to prevent misuse of company funds by controlling shareholders and related parties. The content is regulatory and governance-focused, detailing internal controls, responsibilities of board and management, and legal compliance. It does not contain financial statements, earnings data, or audit results. It is not an announcement or a brief notice but a substantive governance policy document. Therefore, it fits best under Governance Information (CGR). The document length is under 5,000 characters but contains full policy text, not just an announcement, so it is not RPA or RNS.
2025-06-11 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.